The regulatory framework for the use of animals in research in many countries is based on the 3Rs: replacement, reduction, and refinement [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571647 | PMC |
| http://dx.doi.org/10.3390/ani13193063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Considerations for implementing regulation of decapods in science.
Anim Welf
November 2024
Institute of Aquaculture, University of Stirling, Stirling FK9 4LA, UK.
Decapod crustaceans, commonly utilised for pure or applied scientific research and commercial food production, have generally remained outside ethical debate. However, in the last decade many parts of the world have seen an increase in public interest in the welfare of decapod crustaceans and statutory legal protection has been introduced in several countries. Although still limited to a small number of countries and remaining relatively unharmonised, relevant legislation could be increasingly broadened to include decapods in further jurisdictions.
View Article and Find Full Text PDFTo do or not to do: Teaching the skill of deciding what to do in the face of uncertainty.
Aust J Gen Pract
December 2024
MBBS, FRACGP, Grad Cert HPE, Senior Research Fellow, Murray City Country Coast GP Training, Carlton, Vic.
Background: The management of uncertainty is a core general practice skill best learnt in clinical practice.
Objective: This article outlines strategies a general practice supervisor can implement to help registrars acquire the skills of managing and coping with uncertainty.
Discussion: The medical education literature recommends supervisors being explicit about the different paradigm operating in primary care and normalising the existence and tolerance of uncertainty.
PET imaging of GABA receptors in pancreatic islets by [C]flumazenil.
EJNMMI Res
December 2024
Department of Medical Cell Biology, Department of Medical Sciences, Science for Life Laboratory, Uppsala University, Box 571, 75123, Uppsala, Sweden.
Background: Type 1 diabetes (T1D) is an autoimmune disease characterized by a progressive β-cell destruction. There are no clinically established methods for quantifying endocrine cells of the pancreas and current knowledge is almost exclusively based on autopsy material and functional measurements. Based on the expression of the γ-aminobutyric acid A receptors (GABARs) in pancreatic islets and the fact that GABAR agonists are being explored as treatment for T1D, we hypothesized that the positron emission tomography (PET) tracer [C]flumazenil ([C]FMZ) could serve as a marker of the endocrine mass of the pancreas.
View Article and Find Full Text PDFCompact Arterial Monitoring Device Use in Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): A Simple Validation Study in Swine.
Cureus
October 2024
Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, USA.
Article Synopsis
- - Hemorrhage is the main cause of preventable death in trauma situations, leading to military and civilian advancements in medical practices, particularly through the use of tourniquets to manage extremity bleeding and save lives.
- - While tourniquets have significantly decreased deaths from bleeding in military settings, noncompressible hemorrhage still poses a major risk, especially before patients receive definitive medical care.
- - The study explores using a small, disposable pressure monitor during resuscitative endovascular balloon occlusion of the aorta (REBOA) to enhance blood pressure monitoring, facilitate better resuscitation practices, and reduce the need for blood products in extreme environments.
Are Repeat-Dose Toxicity Studies Informative for Safety Assessment of Vaccine Candidates? A Survey of Vaccine Developers.
Int J Toxicol
October 2024
Preclinical Sciences and Translational Safety, JnJ Innovative Medicine, Janssen R&D LLC, A Johnson & Johnson Company, Beerse, Belgium.
A BioSafe-sponsored survey investigated how vaccine companies (n = 12) perceive the value of the repeat-dose toxicity studies for safety assessment of vaccine candidates. As all major vaccine developers were part of the survey, it was considered representative for the industry practices up to 2022. Vaccine developers indicated that they see scientific value in performing repeat-dose toxicity studies with vaccines, especially when novel components (e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!